open access

Vol 26, No 1 (2019)
Original articles — Clinical cardiology
Published online: 2017-11-03
Get Citation

Prognostic value of daytime heart rate, blood pressure, their products and quotients in chronic heart failure

Anna Kowalczys, Michał Bohdan, Marcin Gruchała
DOI: 10.5603/CJ.a2017.0130
·
Pubmed: 29131282
·
Cardiol J 2019;26(1):20-28.

open access

Vol 26, No 1 (2019)
Original articles — Clinical cardiology
Published online: 2017-11-03

Abstract

Background: Chronic heart failure (CHF) is an important epidemiological and therapeuthic issue  with poor prognosis. The aim of the study was to estimate the prognostic value of daytime heart rate (HR), blood pressure (BP), their products and quotients in patients with CHF.

Methods: The study included 80 stable patients with CHF and reduced left ventricular ejection frac- tion (LVEF 35%). Physical examination, laboratory blood tests, electrocardiogram, chest X-ray, echocardiography, 6-minute walk test, telemetry monitoring and BP measurements were performed in all participants. We estimated mean daytime: BP, HR, their products and quotients. The follow-up period was 6 months. Major adverse cardiac events (MACE) included: death, cardiovascular death, hospitalization due to CHF exacerbation. 

Results: The analysis involved all recruited patients with CHF (91% men) aged 59 ± 12 years, in New York Heart Association class 2.15 ± 0.57 and reduced LVEF (mean LVEF: 23 ± 6%). The 3-month and 6-month mortality rates were 4% and 6%, respectively. There was a significant correlation between diastolic blood pressure (DBP), all-cause mortality (p = 0.048) and CHF decompensation (p = 0.0004) after 3-month observation period. No relationship was found between HR or systolic blood pressure (SBP) and MACE. Both higher SBP × HR and DBP × HR products were related to lower risk of heart failure exacerbations during 6-month follow-up. None of the analyzed products or ratios had an impact on mortality in this study group. 

Conclusions: Diastolic blood pressure, SBP × HR and DBP × HR products may be useful in sub- sequent heart failure exacerbation risk stratification. Moreover, DBP value may predict short-term mortality in patients with CHF.  

Abstract

Background: Chronic heart failure (CHF) is an important epidemiological and therapeuthic issue  with poor prognosis. The aim of the study was to estimate the prognostic value of daytime heart rate (HR), blood pressure (BP), their products and quotients in patients with CHF.

Methods: The study included 80 stable patients with CHF and reduced left ventricular ejection frac- tion (LVEF 35%). Physical examination, laboratory blood tests, electrocardiogram, chest X-ray, echocardiography, 6-minute walk test, telemetry monitoring and BP measurements were performed in all participants. We estimated mean daytime: BP, HR, their products and quotients. The follow-up period was 6 months. Major adverse cardiac events (MACE) included: death, cardiovascular death, hospitalization due to CHF exacerbation. 

Results: The analysis involved all recruited patients with CHF (91% men) aged 59 ± 12 years, in New York Heart Association class 2.15 ± 0.57 and reduced LVEF (mean LVEF: 23 ± 6%). The 3-month and 6-month mortality rates were 4% and 6%, respectively. There was a significant correlation between diastolic blood pressure (DBP), all-cause mortality (p = 0.048) and CHF decompensation (p = 0.0004) after 3-month observation period. No relationship was found between HR or systolic blood pressure (SBP) and MACE. Both higher SBP × HR and DBP × HR products were related to lower risk of heart failure exacerbations during 6-month follow-up. None of the analyzed products or ratios had an impact on mortality in this study group. 

Conclusions: Diastolic blood pressure, SBP × HR and DBP × HR products may be useful in sub- sequent heart failure exacerbation risk stratification. Moreover, DBP value may predict short-term mortality in patients with CHF.  

Get Citation

Keywords

chronic heart failure; heart rate; blood pressure; diastolic blood pressure; double product

About this article
Title

Prognostic value of daytime heart rate, blood pressure, their products and quotients in chronic heart failure

Journal

Cardiology Journal

Issue

Vol 26, No 1 (2019)

Pages

20-28

Published online

2017-11-03

DOI

10.5603/CJ.a2017.0130

Pubmed

29131282

Bibliographic record

Cardiol J 2019;26(1):20-28.

Keywords

chronic heart failure
heart rate
blood pressure
diastolic blood pressure
double product

Authors

Anna Kowalczys
Michał Bohdan
Marcin Gruchała

References (42)
  1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  2. Nessler J, Skrzypek A. Chronic heart failure in the elderly: a current medical problem. Pol Arch Med Wewn. 2008; 118(10): 572–580.
  3. Bjurman C, Holmström A, Petzold M, et al. Assessment of a multi-marker risk score for predicting cause-specific mortality at three years in older patients with heart failure and reduced ejection fraction. Cardiol J. 2015; 22(1): 31–36.
  4. Jarosz M, Wolańska D, Stolińska H, et al. Nutrition and lifestyle in patients pharmacologically treated due to hypertensionally treated due to hypertension. Cardiol J. 2016 [Epub ahead of print].
  5. Lee TT, Chen J, Cohen DJ, et al. The association between blood pressure and mortality in patients with heart failure. Am Heart J. 2006; 151(1): 76–83.
  6. Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009; 95(1): 56–62.
  7. Grigorian-Shamagian L, Gonzalez-JuAnatey JR, Vazquez R, et al. Association of blood pressure and its evolving changes with the survival of patients with heart failure. J Card Fail. 2008; 14(7): 561–568.
  8. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103–2116.
  9. Bavishi C, Bangalore S, Messerli FH. Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. J Am Coll Cardiol. 2017; 69(5): 486–493.
  10. McLaren DP, Jones R, Plotnik R, et al. Prior hospital admission predicts thirty-day hospital readmission for heart failure patients. Cardiol J. 2016; 23(2): 155–162.
  11. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004; 26(7-8): 637–644.
  12. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26(10): 967–974.
  13. Cowie MR, Fox KF, Wood DA, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000; 83(5): 505–510.
  14. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–885.
  15. Gobel FL, Norstrom LA, Nelson RR, et al. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 1978; 57(3): 549–556.
  16. Villella M, Villella A, Barlera S, et al. Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI-2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell-Infarto Miocardico. Am Heart J. 1999; 137(3): 443–452.
  17. Inoue R, Ohkubo T, Kikuya M, et al. Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study. Am J Hypertens. 2012; 25(5): 568–575.
  18. Schutte R, Thijs L, Asayama K, et al. Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants. Am J Hypertens. 2013; 26(5): 665–672.
  19. Brophy JM, Dagenais GR, McSherry F, et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004; 116(5): 300–304.
  20. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003; 290(19): 2581–2587.
  21. Ghali JK, Kadakia S, Bhatt A, et al. Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure. Am Heart J. 1992; 123(4 Pt 1): 993–997.
  22. Lip GYH, Skjøth F, Overvad K, et al. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. Clin Res Cardiol. 2015; 104(12): 1088–1096.
  23. Berry M, Lairez O, Fourcade J, et al. Prognostic value of systolic short-term blood pressure variability in systolic heart failure. Clin Hypertens. 2016; 22: 16.
  24. Sherazi S, McNitt S, Choudhary N, et al. Predictors of mortality in patients hospitalized for congestive heart failure with left ventricular ejection fraction ≥ 40. Cardiol J. 2015; 22(4): 382–390.
  25. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-Pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374(21): 2009–2020.
  26. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006; 144(12): 884–893.
  27. McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016; 68(16): 1713–1722.
  28. Voors AA, Ouwerkerk W, Zannad F, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017; 19(5): 627–634.
  29. Uszko-Lencer NH, Frankenstein L, Spruit MA, et al. Predicting hospitalization and mortality in patients with heart failure: The BARDICHE-index. Int J Cardiol. 2017; 227: 901–907.
  30. Rihal CS, Nishimura RA, Hatle LK, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994; 90(6): 2772–2779.
  31. Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43(8): 1439–1444.
  32. Cowie MR, Davidson L. Clinical perspective: the importance of heart rate reduction in heart failure. Int J Clin Pract. 2012; 66(8): 728–730.
  33. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999; 1(Suppl. H): H64–9.
  34. McAlister FA, Wiebe N, Ezekowit JA, et al. Heart rate reduction and death in patients with heart failure. Ann Intern Med. 2009; 150: 784–94.
  35. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32(19): 2395–2404.
  36. Zou C, Dong H, Wang F, et al. Heart acceleration and deceleration capacities associated with dilated cardiomyopathy. Eur J Clin Invest. 2016; 46(4): 312–320.
  37. Cullington D, Goode KM, Zhang J, et al. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail. 2014; 2(3): 213–220.
  38. Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of β-Blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the swedish heart failure registry. Circ Heart Fail. 2015; 8(5): 871–879.
  39. Sánchez-Gil J, Manzano L, Flather M, et al. RICA investigators. Combining heart rate and systolic blood pressure to improve risk stratification in older patients with heart failure: Findings from the RICA Registry. Int J Cardiol. 2017; 230: 625–629.
  40. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999; 12(2 Pt 2): 50S–55S.
  41. Buffington CW, Sivarajan M, Bashein G. The quotient of mean arterial pressure and heart rate predicts hypoperfusion of collateral-dependent myocardium. J Cardiothorac Anesth. 1989; 3(1): 65–69.
  42. Mereu R, De Barbieri G, Perrone T, et al. Heart rate/blood pressure ratio as predictor of neuromediated syncope. Int J Cardiol. 2013; 167(4): 1170–1175.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl